Google
Trusted Resources: News & Events
Latest announcements and gatherings
Nobel Prize Spotlights Sickle Cell’s Disproportionate Impact on African Americans
This summer, 34-year-old Victoria Gray became the first person in the U.S. to have a gene editing therapy as treatment for sickle cell disease. “It’s a very big deal for me,” Gray said in a national media interview after learning the groundbreaking treatment was working. “It’s the change I’ve been waiting on my whole life.”
Gray, a Black wife and a mother of three from Mississippi, had been living with the complications of the inherited blood disorder that disproportionately affects African Americans for her entire life.
CRISPR is a new technique that involves cutting out a tiny piece of the mutation or defective gene that causes sickle cell disease in the hopes that the corrected gene will then work to make normal hemoglobin (a protein in red blood cells) instead of the sickle-shaped hemoglobin that gives the disease its name.
+myBinderRelated Content
-
Women with Sickle Cell Disease and Prenatal Care: What to Know During PregnancyPrenatal care is health care you get whi...
-
Pfizer rare disease introduces Council for Change to further help SCD patientsFollowing a report earlier thi...
-
Longitudinal Analysis of Patient Specific Predictors for Mortality in Sickle Cell DiseaseINTRODUCTION: White Blood Cell (WBC) cou...
-
The Regional Comprehensive Sickle Cell Center at Robert Wood Johnson Medical SchoolThe Division of Hematology provides spec...
-
Finding the right sickle cell disease care teamChandra Wallace does not remember a time...
-
Siri saves sick girl from Harvey floodwatersStranded outside in the rising waters of...
-
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)AmerisourceBergen, a global healthcare s...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.